A Plus Biotechnology Co (TPE:6918) Change In Receivables: NT$-5.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6918 A Plus Biotechnology Co Ltd TPE:6918
74 GF Score
Price NT$78.00
GF Value NT$86.69
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is A Plus Biotechnology Co Change In Receivables?

A Plus Biotechnology Co TPE:6918 +4.70% 74 Change In Receivables is NT$-5.0 Mil as of Jun. 2026. GuruFocus rates TPE:6918 with a GF Score™ of 74/100 and a GF Value™ of NT$86.69 (Modestly Undervalued). The stock has 4 warning signs investors should review.

A Plus Biotechnology Co's change in receivables for the quarter that ended in Jun. 2026 was NT$1.2 Mil. It means A Plus Biotechnology Co's Accounts Receivable declined by NT$1.2 Mil from Mar. 2026 to Jun. 2026 .

A Plus Biotechnology Co's change in receivables for the fiscal year that ended in Dec. 2025 was NT$6.5 Mil. It means A Plus Biotechnology Co's Accounts Receivable declined by NT$6.5 Mil from Dec. 2024 to Dec. 2025 .

A Plus Biotechnology Co's Accounts Receivable for the quarter that ended in Jun. 2026 was NT$180.0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. A Plus Biotechnology Co's Days Sales Outstanding for the three months ended in Jun. 2026 was 67.63.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. A Plus Biotechnology Co's liquidation value for the three months ended in Jun. 2026 was NT$454.5 Mil.

A Plus Biotechnology Co  (TPE:6918) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

A Plus Biotechnology Co's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=180.042/242.938*91
=67.63

2. In Ben Graham's calculation of liquidation value, A Plus Biotechnology Co's accounts receivable are only considered to be worth 75% of book value:

A Plus Biotechnology Co's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=481.558-345.577+0.75 * 180.042+0.5 * 366.998
=454.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A Plus Biotechnology Co Change In Receivables Related Terms

A Plus Biotechnology Co Change In Receivables Historical Data

* Premium members only.

The historical data trend for A Plus Biotechnology Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A Plus Biotechnology Co Change In Receivables Chart

A Plus Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial 0.73 -21.67 4.38 -42.26 6.47

A Plus Biotechnology Co Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.71 -11.63 7.36 -1.91 1.22
TPE:6918
74GF Score
A Plus Biotechnology Co Ltd TPE:6918
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

A Plus Biotechnology Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-5.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of NT$-5.0 Mil mean?
A Plus Biotechnology Co (TPE:6918) has a Change In Receivables of NT$-5.0 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for A Plus Biotechnology Co and its competitors.
Is A Plus Biotechnology Co's Change In Receivables too high?
A Plus Biotechnology Co's current Change In Receivables is NT$-5.0 Mil. Overall, A Plus Biotechnology Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's Change In Receivables compare to ABT and SYK?
A Plus Biotechnology Co's Change In Receivables of NT$-5.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for A Plus Biotechnology Co and its competitors. A Plus Biotechnology Co's current Change In Receivables is NT$-5.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$86.69, compared to a current price of NT$78.00 — trading 10% below its estimated fair value. The current Change In Receivables is NT$-5.0 Mil. A Plus Biotechnology Co's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current Change In Receivables is NT$-5.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?

Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued. The current stock price of NT$78.00 is trading 10% below its estimated GF Value™ of NT$86.69. GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.

Key valuation signals for TPE:6918:

  • Change In Receivables: NT$-5.0 Mil
  • GF Value™: NT$86.69 vs. price of NT$78.00 (10% below fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

A Plus Biotechnology Co Business Description

Address No. 21, Qiaohe Road, 3rd Floor, Zhonghe District, New Taipei City, TWN
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
74GF Score

Get the complete analysis for TPE:6918

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$78.00
Price
NT$86.69
GF Value